# Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02299375** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 184 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Losmapimod tablets
- **DRUG:** Placebo tablets
- **DRUG:** Salbutamol MDI

## Key facts

- **NCT ID:** NCT02299375
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-09
- **Primary completion:** 2016-06-30
- **Final completion:** 2016-06-30
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2018-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02299375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02299375, "Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02299375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*